This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
by Sundeep Ganoria
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs earnings pharmaceuticals
Will Positive Regulatory Updates Further Boost INCY Stock?
by Zacks Equity Research
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
GSKNegative Net Change NVSPositive Net Change QGENPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
by Kanishka Das
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
Biotech ETFs Bounce Back in 2025: Here's Why
by Sanghamitra Saha
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
IBBPositive Net Change SPYPositive Net Change BBCPositive Net Change SBIOPositive Net Change BBPPositive Net Change ARKGPositive Net Change CANCPositive Net Change
biotechnology biotechs etfs
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
by Zacks Equity Research
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
by Sundeep Ganoria
VKTX is likely to have headed into Q3 earnings with no product revenue, pipeline updates in focus and widening loss forecasts testing investor patience.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
by Zacks Equity Research
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
AZNPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Halozyme Rallies Almost 40% YTD: How Should You Play the Stock?
by Kanishka Das
HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.
RHHBYNegative Net Change JNJNegative Net Change HALOPositive Net Change
biotechs
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
by Zacks Equity Research
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
ALNYPositive Net Change ANIPNegative Net Change VTRSNo Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
by Zacks Equity Research
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
NVONegative Net Change LLYPositive Net Change OMERNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
by Sundeep Ganoria
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)
by Zacks Equity Research
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs gene-therapy pharmaceuticals
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
by Zacks Equity Research
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
ALNYPositive Net Change ANIPNegative Net Change RCKTPositive Net Change CMMBPositive Net Change
biotechs
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
ALNYPositive Net Change BCRXPositive Net Change CRMDNegative Net Change ATXSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
by Ekta Bagri
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
AZNPositive Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
by Sundeep Ganoria
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
RHHBYNegative Net Change PFEPositive Net Change NVONegative Net Change
biotechs medical pharmaceuticals
Bitfarms Soars 428% in 3 Months: Buy, Sell or Hold the Stock?
by Arghyadeep Bose
BITF's ambitious pivot to AI and high-performance computing gains traction with major U.S. projects and strong funding support.
MARAPositive Net Change RIOTNegative Net Change BITFNegative Net Change
artificial-intelligence biotechs business-services internet tech-stocks
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
ALNYPositive Net Change ALLOPositive Net Change CMMBPositive Net Change TVRDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
by Kanishka Das
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
GSKNegative Net Change MIRMPositive Net Change TVTXPositive Net Change
biotechs
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
by Ahan Chakraborty
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
by Zacks Equity Research
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
BIIBPositive Net Change FOLDPositive Net Change CRMDNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
by Zacks Equity Research
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
RHHBYNegative Net Change JNJNegative Net Change PFEPositive Net Change PTGXPositive Net Change
biotechs medical pharmaceuticals
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve
by Zacks Equity Research
AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.
AZNPositive Net Change PFEPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
by Zacks Equity Research
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
ADCTNegative Net Change ZTSNegative Net Change ALLOPositive Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals